NasdaqGS:DERM

Stock Analysis Report

Executive Summary

Dermira, Inc., a biopharmaceutical company, develops and commercializes therapies for patients with dermatologic diseases in the United States.

Snowflake

Fundamentals

Limited growth with imperfect balance sheet.


Similar Companies

Share Price & News

How has Dermira's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0.2%

NasdaqGS:DERM

-0.05%

US Pharmaceuticals

0.9%

US Market


1 Year Return

-10.4%

NasdaqGS:DERM

-6.7%

US Pharmaceuticals

0.3%

US Market

DERM underperformed the Pharmaceuticals industry which returned -6.9% over the past year.

DERM underperformed the Market in United States of America which returned -0.5% over the past year.


Share holder returns

DERMIndustryMarket
7 Day0.2%-0.05%0.9%
30 Day2.1%-1.4%-1.9%
90 Day-14.0%-3.1%1.6%
1 Year-10.4%-10.4%-4.4%-6.7%2.6%0.3%
3 Year-74.7%-74.7%9.4%2.0%41.0%31.8%
5 Yearn/a24.0%10.9%55.2%38.0%

Price Volatility Vs. Market

How volatile is Dermira's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Dermira undervalued based on future cash flows and its price relative to the stock market?

7.1x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Dermira to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Dermira to establish if it is available at substantial discount.


Price Based on Earnings

Dermira is loss making, we can't compare its value to the US Pharmaceuticals industry average.

Dermira is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Dermira, we can't assess if its growth is good value.


Price Based on Value of Assets

Dermira is overvalued based on assets compared to the US Pharmaceuticals industry average.


Next Steps

Future Growth

How is Dermira expected to perform in the next 1 to 3 years based on estimates from 8 analysts?

24.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Dermira's revenue is expected to grow significantly at over 20% yearly.

Dermira is not considered high growth as it is expected to be loss making for the next 1-3 years.

Dermira's revenue growth is expected to exceed the United States of America market average.

Unable to compare Dermira's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.

Unable to compare Dermira's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Dermira will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Dermira performed over the past 5 years?

-39.4%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Dermira does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Dermira's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Dermira's 1-year growth to the US Pharmaceuticals industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Dermira has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Dermira has efficiently used its assets last year compared to the US Pharmaceuticals industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Dermira improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Dermira's financial position?


Financial Position Analysis

Dermira is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Dermira's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Dermira's level of debt (480.3%) compared to net worth is high (greater than 40%).

The level of debt compared to net worth has increased over the past 5 years (4.1% vs 480.3% today).


Balance Sheet

Low level of unsold assets.

Debt is covered by short term assets, assets are 1.4x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Dermira has less than a year of cash runway based on current free cash flow.

Dermira has less than a year of cash runway if free cash flow continues to grow at historical rates of 54.6% each year.


Next Steps

Dividend

What is Dermira's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Dermira's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Dermira's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Dermira has not reported any payouts.

Unable to verify if Dermira's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Dermira has not reported any payouts.


Future Payout to Shareholders

No need to calculate the sustainability of Dermira's dividends in 3 years as they are not expected to pay a notable one for United States of America.


Next Steps

Management

What is the CEO of Dermira's salary, the management and board of directors tenure and is there insider trading?

5.5yrs

Average management tenure


CEO

Tom Wiggans (67yo)

9.0yrs

Tenure

US$4,371,178

Compensation

Mr. Thomas G. Wiggans, also known as Tom, co-founded Dermira, Inc. in August 2010 and has been its Chief Executive Officer since August 2010. Mr. Wiggans serves as an Advisor at Stiefel Laboratories. He ha ...


CEO Compensation Analysis

Tom's remuneration is higher than average for companies of similar size in United States of America.

Tom's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

5.5yrs

Average Tenure

52yo

Average Age

The average tenure for the Dermira management team is over 5 years, this suggests they are a seasoned and experienced team.


Board Age and Tenure

5.3yrs

Average Tenure

60.5yo

Average Age

The tenure for the Dermira board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Tom Wiggans (67yo)

    Co-Founder

    • Tenure: 9.0yrs
    • Compensation: US$4.37m
  • Andrew Guggenhime (51yo)

    Chief Financial Officer

    • Tenure: 5.3yrs
    • Compensation: US$2.36m
  • Gene Bauer (77yo)

    Co-Founder

    • Tenure: 9.0yrs
    • Compensation: US$1.86m
  • Chris Griffith (43yo)

    Co-Founder and Chief Business & Strategy Officer

    • Tenure: 9.0yrs
    • Compensation: US$833.15k
  • Luis Peña (56yo)

    Co-Founder & Chief Development Officer

    • Tenure: 0.0yrs
    • Compensation: US$2.52m
  • Chris Horan (52yo)

    Chief Technical Operations Officer

    • Tenure: 1.3yrs
    • Compensation: US$2.36m
  • Christine Ring

    Vice President for Legal

    • Tenure: 5.0yrs
  • Lori Lyons-Williams (42yo)

    Chief Commercial Officer

    • Tenure: 2.7yrs
    • Compensation: US$2.70m
  • Mary Sillivos

    Vice President of Human Resources

    • Tenure: 5.6yrs
  • Erica Jefferson

    Vice President of Corporate Communications

    • Tenure: 0.0yrs

Board Members

  • Tom Wiggans (67yo)

    Co-Founder

    • Tenure: 9.0yrs
    • Compensation: US$4.37m
  • Fred Craves (73yo)

    Lead Independent Director

    • Tenure: 0.0yrs
    • Compensation: US$140.23k
  • Gene Bauer (77yo)

    Co-Founder

    • Tenure: 9.0yrs
    • Compensation: US$1.86m
  • Jake Nunn (49yo)

    Non-Employee Director

    • Tenure: 8.3yrs
    • Compensation: US$115.23k
  • Howard Maibach

    Scientific Advisor

    • Tenure: 0.0yrs
  • Matt Fust (54yo)

    Non-Employee Director

    • Tenure: 5.3yrs
    • Compensation: US$128.73k
  • Seth Orlow

    Scientific Advisor

    • Tenure: 0.0yrs
  • David Cohen (54yo)

    Non-Employee Director

    • Tenure: 5.2yrs
    • Compensation: US$133.73k
  • Brian Berman

    Scientific Advisor

    • Tenure: 0.0yrs
  • Sewon Kang

    Scientific Advisor

    • Tenure: 0.0yrs

Company Information

Dermira, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Dermira, Inc.
  • Ticker: DERM
  • Exchange: NasdaqGS
  • Founded: 2010
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$465.646m
  • Shares outstanding: 54.40m
  • Website: https://www.dermira.com

Number of Employees


Location

  • Dermira, Inc.
  • 275 Middlefield Road
  • Suite 150
  • Menlo Park
  • California
  • 94025
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
DERMNasdaqGS (Nasdaq Global Select)YesCommon SharesUSUSDOct 2014
19DDB (Deutsche Boerse AG)YesCommon SharesDEEUROct 2014

Biography

Dermira, Inc., a biopharmaceutical company, develops and commercializes therapies for patients with dermatologic diseases in the United States. The company offers QBREXZA, a topical once-daily anticholiner ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/20 00:31
End of Day Share Price2019/08/19 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.